Axplora has announced a €6.5 million investment at its Vizag manufacturing site in India, aimed at expanding active pharmaceutical ingredient (API) production and reinforcing global supply chain resilience. The news follows successful 2025 US Food and Drug Administration (FDA) inspections at both Vizag and Chennai facilities, which are part of the company’s PharmaZell business unit.

The Vizag site expansion will increase production output and create new jobs, while supporting a vertically integrated, single-site manufacturing approach intended to boost operational efficiency and sustainability.

“This investment reflects Axplora’s strategic commitment to operational excellence and customer-centric growth,” said Martin Meeson, chief executive officer of Axplora. “By strengthening our infrastructure in Vizag, we are enhancing our ability to deliver high-quality, reliable, and scalable solutions to customers worldwide.”

Both Indian sites underwent routine FDA inspections earlier this year, each concluding with a Voluntary Action Indicated (VAI) classification. According to the company, these outcomes reflect continued adherence to international regulatory standards and a proactive approach to continuous improvement.

At the Chennai facility, FDA inspectors noted several areas of excellence, including implementation of current good manufacturing practices (cGMP), document management processes, and high site hygiene standards.

“These results are a powerful validation of our team’s diligence and our unwavering focus on quality,” said Anant Barbadikar, co-president of PharmaZell and chief operating officer for India. “The success of both inspections reflects not just regulatory compliance, but the operational integrity and continuous improvement culture we strive to embed across every Axplora site.”

The company stated that observations raised during the inspections are being addressed through formal corrective actions and acknowledged the contribution of site teams in preparing for and completing the inspection process.

The €6.5 million investment at Vizag marks the latest step in Axplora’s long-term strategy to scale API production capabilities in key global regions, while supporting sustainable operations. With increased capacity at Vizag and regulatory performance confirmed at both Indian sites, Axplora is reinforcing its position as a reliable partner for small molecule drug development and commercial supply.